The pharmacological treatment of opioid addiction - A clinical perspective

European Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2010, Pages 537-545

  Lobmaier, Philipp ^a,b   Gossop, Michael ^b,c   Waal, Helge ^b   Bramness, Jorgen ^a,b,d  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Buprenorphine; Detoxification; Methadone; Naltrexone; Opioid addiction; Opioid maintenance treatment; Review

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; CODEINE; DIAMORPHINE; LEVACETYLMETHADOL; LOFEXIDINE; METHADONE; MORPHINE SULFATE; NALOXONE; NALTREXONE; PLACEBO; SUBSTITOL; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ALCOHOLISM; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DETOXIFICATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART DISEASE; HEROIN DEPENDENCE; HUMAN; HYPOTENSION; MAINTENANCE THERAPY; MYALGIA; NAUSEA; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QT PROLONGATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; TREATMENT DURATION; VOMITING; WITHDRAWAL SYNDROME; DRUG COMBINATION; DRUG DETOXIFICATION; PSYCHOLOGICAL ASPECT; SOCIAL SUPPORT;

ADRENERGIC AGONISTS; ANALGESICS, OPIOID; BUPRENORPHINE; CLONIDINE; DRUG THERAPY, COMBINATION; HUMANS; METABOLIC DETOXICATION, DRUG; METHADONE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SOCIAL SUPPORT; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77954908389     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0793-6     Document Type: Review

References (113)

1. EMCDDA (2008) The state of the drugs problem in Europe. EuropeanMonitoring Centre for Drugs and Drug Addiction, Lisbon
2. Nestler EJ (2001)Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2(2):119-128
3. Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 (Suppl 2):S91-S117
4. Simpson DD, Sells SB (1990) Opioid addiction and treatment. Robert E. Krieger, Malabar
5. Gowing L, Farrell M, Ali R, White JM (2009) Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2:CD002024. doi:10.1002/14651858.CD002024.pub3
6. Kreek MJ (2000) Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N YAcad Sci 909:186-216
7. Amato L, Davoli M, Minozzi S, Ali R, Ferri M (2005) Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 3:CD003409. doi:10.1002/14651858.CD003409.pub3
8. Gossop M, Griffiths P, Bradley B, Strang J (1989) Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. Br J Psychiatry 154:360-363
9. Strang J, Gossop M (1990) Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts. Addict Behav 15(6):541-547
10. Gowing L, Ali R, White JM (2009) Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 3:CD002025. doi:10.1002/14651858. CD002025.pub4
11. Reed LJ, Glasper A, de Wet CJ, Bearn J, Gossop M (2007) Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients? J Clin Psychopharmacol 27(2):188-192
12. Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21(3):253-259
13. Buntwal N, Bearn J, Gossop M, Strang J (2000) Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. Drug Alcohol Depend 59(2):183-188
14. Bearn J, Gossop M, Strang J (1998) Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 50(3):227-232
15. Strang J, Bearn J, Gossop M (1999) Lofexidine for opiatedetoxification: review of recent randomised and open controlled trials. Am J Addict 8(4):337-348
16. Bearn J, Gossop M, Strang J (1999) Rapid opiate detoxification treatments. Drug Alcohol Rev 18(1):75-81
17. Collins ED, Kleber HD, Whittington RA, Heitler NE (2005) Anesthesia-assisted vs buprenorphine-or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 294(8):903-913
18. Unnithan S, Gossop M, Strang J (1992) Factors associated with relapse among opiate addicts in an out-patient detoxification programme. Br J Psychiatry 161:654-657
19. Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML (2001) One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse 27(1):19-44
20. Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S et al (2003) Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 326(7396):959-960
21. Ward J, Hall W, Mattick RP (1999) Role of maintenance treatment in opioid dependence. Lancet 353(9148):221-226
22. Buster MC, van Brussel GH, Van den Brink W (2002) An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 97(8):993-1001
23. Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L (2009) A metaanalysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse 35(1):28-33
24. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P (2003) Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 3:CD002208. doi:10.1002/14651858.CD002208
25. WHO (2009) Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. http://whqlibdoc.who.int/publications/2009/ 9789241547543-eng.pdf. Accessed 16 January 2010
26. Mattick RP, Breen C, Kimber J, Davoli M (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 3:CD002209. doi:10.1002/14651858.CD002209.pub2
27. Amato L, Davoli M, Perucci A, Ferri M, Faggiano F, Mattick P (2005) An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 28(4):321-329
28. Marsch LA (1998) The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 93(4):515-532
29. Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM (1994) Retention in methadone maintenance and heroin addicts' risk of death. Addiction 89(2):203-209
30. Gossop M, Marsden J, Stewart D, Treacy S (2001) Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Dep 62(3):255-264
31. Skeie I, Brekke M, Lindbaek M, Waal H (2008) Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study. BMC Public Health 8:43
32. Clausen T, Anchersen K, Waal H (2008) Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 94(1-3):151-157
33. Torrens M, Domingo-Salvany A, Alonso J, Castillo C, San L (1999) Methadone and quality of life. Lancet 353(9158):1101
34. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H et al (1993) Human immunodeficiency virus seroconversion among intravenous drug users in-and out-oftreatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6(9):1049-1056
35. Hubbard RL, Craddock SG, Anderson J (2003) Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 25(3):125-134
36. Gossop M, Marsden J, Stewart D, Kidd T (2003) The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction 98(3):291-303
37. Magura S, Rosenblum A (2001) Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 68(1):62-74
38. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B et al (2006) Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 166(12):1280-1287
39. Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A (2005) QTc interval prolongation in patients on longterm methadone maintenance therapy. Eur Addict Res 11(1):44-49
40. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H (2009) Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 104(6):993-999
41. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD (2003) A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 72(1):59-65
42. Kandall SR, Doberczak TM, Jantunen M, Stein J (1999) The methadone-maintained pregnancy. Clin Perinatol 26(1):173-183
43. Bakstad B, Sarfi M, Welle-Strand G, Ravndal E (2009) Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. Eur Addict Res 15:128-134
44. Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274(1):361-372
45. Dollery CT (1991) Therapeutic drugs, 1st edn. Churchill Livingstone, Edinburgh
46. Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14(3-4):363-372
47. Johnson RE, Cone EJ, Henningfield JE, Fudala PJ (1989) Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 46(3):335-343
48. Boysen K, Hertel S, Chraemmer-Jorgensen B, Risbo A, Poulsen NJ (1988) Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia. Acta Anaesthesiol Scand 32(6):490-492
49. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD (1996) Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 20(6):369-378
50. Cone EJ, Dickerson S, DarwinWD, Fudala PJ, Johnson RE (1990) Elevated drug saliva levels suggests a depot-like effect in subjects treated with sublingual buprenorphine. NIDA Res Monogr 105:569
51. Ahmadi J, Babaee-Beigi M, Alishahi M, Maany I, Hidari T (2004) Twelve-month maintenance treatment of opiumdependent patients. J Subst Abuse Treat 26(1):363-366
52. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE (1995) A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40(1):17-25
53. Kakko J, Svanborg KD, Kreek MJ, Heilig M (2003) 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361(9358):662-668
54. Krook AL, Brors O, Dahlberg J, Grouff K, Magnus P, Roysamb E et al (2002) A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 97(5):533-542
55. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P et al (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93(4):475-486
56. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL (2000) Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 60(1):39-50
57. Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR (2005) Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 162(2):340-349
58. Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D (1998) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. Eur Addict Res 4(Suppl 1):13-18
59. Ahmadi J (2003) Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 24(3):217-220 (Pubitemid 37297338)
60. Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G et al (1999) Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94(9):1337-1347 (Pubitemid 29433792)
61. Johnson RE, Jaffe JH, Fudala PJ (1992) A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267 (20):2750-2755
62. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J (1993) Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 181(6):358-364 (Pubitemid 24259606)
63. Ling W, Wesson DR, Charuvastra C, Klett CJ (1996) A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53(5):401-407
64. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C (2003) Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 98(4):441-452
65. Neri S, Bruno CM, Pulvirenti D, Malaguarnera M, Italiano C, Mauceri B et al (2005) Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology 179(3):700-704
66. Petitjean S, Stohler R,Deglon JJ, Livoti S, Waldvogel D, Uehlinger C et al (2001) Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 62(1):97-104
67. Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151(7):1025-1030
68. Mattick RP, Kimber J, Breen C, Davoli M (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2:CD002207. doi:10.1002/14651858.CD002207.pub3 (Pubitemid 351807246)
69. Fatseas M, Auriacombe M (2007) Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 9(5):358-364
70. Thirion X, Lapierre V, Micallef J, Ronfle E, Masut A, Pradel Vet al (2002) Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 65(2):197-204
71. Feroni I, Peretti-Watel P, Paraponaris A, Masut A, Ronfle E,Mabriez JC et al (2005) French general practitioners' attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse? J Addict Dis 24(3):7-22
72. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J (2004) French field experience with buprenorphine. Am J Addict 13(Suppl 1):S17-S28
73. Bouchez J, Beauverie P, Touzeau D (1998) Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. Preliminary results. Eur Addict Res 4(Suppl 1):8-12
74. Kayemba-Kay's S, Laclyde JP (2003) Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 98 (11):1599-1604
75. Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM et al (2001) Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 63(1):97-103
76. Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M et al (2000) Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95(2):239-244 (Pubitemid 30111244)
77. Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE et al (2005) Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79(1):1-10
78. Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M et al (2006) Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 101(2):275-281
79. Fiellin DA (2006) Buprenorphine: effective treatment of opioid addiction starts in the office. Am Fam Physician 73(9):1513-1514
80. Bell J, Byron G, Gibson A, Morris A (2004) A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 23(3):311-317
81. Naomi Study Team (2009) Reaching the hardest to reach - treating the hardest-to-treat. Summary of the primary outcomes of NAOMI. North American Opiate Medication Initiative, Vancouver&Montreal
82. Metrebian N, Carnwath T, Stimson GV, Storz T (2002) Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction 97(9):1155-1161
83. Hartnoll RL, Mitcheson MC, Battersby A, Brown G, Ellis M, Fleming P et al (1980) Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 37(8):877-884
84. Brehmer C, Iten PX (2001) Medical prescription of heroin to chronic heroin addicts in Switzerland - a review. Forensic Sci Int 121(1-2):23-26
85. Blanken P, Hendriks VM, Koeter MW, Van Ree JM, Van den Brink W (2005) Matching of treatment-resistant heroindependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Addiction 100(1):89-95
86. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D (2007) Heroin-assisted treatment for opioid dependence: randomisedcontrolled trial. Br J Psychiatry 191:55-62
87. Ferri-Marica MF, Davoli M, Perucci-Carlo AA (2005) Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev 2:CD003410. doi:10.1002/14651858.CD003410.pub2
88. Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G (2005) Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 100(8):1101-1109
89. Mitchell TB, White JM, Somogyi AA, Bochner F (2004) Slowrelease oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 99(8):940-945
90. Kastelic A, Dubajic G, Strbad E (2008) Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 103(11):1837-1846
91. Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG (2007) Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 164(11):1750-1756
92. Krausz M (2003) Alternative opoids-maintenance treatment for opiate addicts with codeine and morphine. In: Waal H, Haga E (eds) Maintenance treatment of heroin addcition. Evidence at the crossroads. Cappelen Akademiske, Oslo, pp 121-129
93. Bachs L, Skurtveit S, Morland J (2003) Codeine and clinical impairment in samples in which morphine is not detected. Eur J Clin Pharmacol 58(12):785-789
94. Clark NC, Lintzeris N, Gijsbers A, Whelan G, Dunlop A, Ritter A, et al (2002) LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst Rev 2: CD002210. doi:10.1002/14651858.CD002210
95. Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet 1(3):219-230
96. Handal KA, Schauben JL, Salamone FR (1983) Naloxone. Ann Emerg Med 12(7):438-445
97. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2006) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 1:CD001333. doi:10.1002/14651858.CD001333.pub2
98. Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, EgorovaVYet al (2004) Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 26(4):285-294
99. San L, Pomarol G, Peri JM, Olle JM, Cami J (1991) Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 86(8):983-990
100. Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y (1994) The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 35(12):935-945
101. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B et al (1997) Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 14(6):529-534
102. Ladewig D (1990) Naltrexone - an effective aid in the psychosocial rehabilitation process of former opiate dependent patients. Ther Umsch 47(3):247-250
103. Gonzalez JP, Brogden RN (1988) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35 (3):192-213
104. Schottenfeld RS, Chawarski MC, Mazlan M (2008) Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 371(9631):2192-2200
105. Julius D (1976) NIDA's naltrexone research program. NIDA Res Monogr 9:5-11
106. Washton AM, Pottash AC, Gold MS (1984) Naltrexone in addicted business executives and physicians. J Clin Psychiatry 45(9 Pt 2):39-41
107. Willette RE (1978) The development of sustained action preparations of narcotic antagonists. NIDA Res Monogr 19:333-339
108. Lobmaier P, Kornor H, Kunoe N, Bjorndal A (2008) Sustainedrelease naltrexone for opioid dependence. Cochrane Database Syst Rev 2:CD006140. doi:10.1002/14651858.CD006140.pub2 (Pubitemid 351807436)
109. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K et al (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebocontrolled trial. Arch Gen Psychiatry 63(2):210-218
110. Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M et al (2009) Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 194(6):541-546
111. Hulse GK, Morris N, Arnold-Reed D, Tait RJ (2009) Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 66(10):1108-1115
112. O'Brien B, Cody C (2006) Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge. Eur J Emerg Med 13(5):315-316
113. Bramness JG, Kornor H (2007) Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 90(2-3):203-209